tirzepatide gastrointestinal side effects Explained: The Future of Weight Management In adult patients with obesity

VK2809, a novel liver-directed thyroid receptor agonist, produces durable reductions in liver fat in patients with non-alcoholic fatty liver disease: Results of 4-week follow-up assessment from a 12-week Phase 2 randomized, placebo-controlled trial Novel first-in-class, fatty acid synthase inhibitor, TVB-2640 versus placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH: A phase 2 randomized controlled trial (FASCINATE-1) Magnetic resonance imaging-proton density fat fraction (MRI-PDFF) to predict treatment response on NASH liver biopsy: a secondary analysis of the resmetirom randomized placebo controlled Phase 2 clinical trial Multifactorial Effects of AXA1125 and AXA1957 Observed on Markers of Metabolism, Inflammation and Fibrosis: A 16-Week Randomized Placebo-Controlled Study in Subjects With Nonalcoholic Fatty Liver Disease (NAFLD) With and Without Type 2 Diabetes (T2D) Hong CW, et al

Cell Metab 2025;37:429440.e5

Numerous studies have demonstrated that liposomal tranexamic acid was effective in approximately 80% of participants during an 8-week of treatment course (Manosroi et al., 2002)

Ideal for everyone from professional athletes to the average person, it's packaged using veggie caps and sealed in a convenient bottle

Bailey Bryan is a healthcare communications specialist at Call-On-Doc with over three years of experience helping patients access reliable, high-quality care